Home » Stocks » OMCL

Omnicell, Inc. (OMCL)

Stock Price: $129.40 USD 2.50 (1.97%)
Updated Mar 1, 2021 4:00 PM EST - Market closed
Market Cap 5.58B
Revenue (ttm) 892.21M
Net Income (ttm) 32.19M
Shares Out 42.58M
EPS (ttm) 0.74
PE Ratio 174.86
Forward PE 37.59
Dividend n/a
Dividend Yield n/a
Trading Day March 1
Last Price $129.40
Previous Close $126.90
Change ($) 2.50
Change (%) 1.97%
Day's Open 128.72
Day's Range 127.51 - 130.74
Day's Volume 197,708
52-Week Range 54.24 - 137.99

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 3 weeks ago

Omnicell's (OMCL) fourth-quarter 2020 revenues rose 0.36% year over year to $249.2 million, improving 16.1% sequentially.

Seeking Alpha - 1 month ago

Omnicell, Inc. (OMCL) CEO Randall Lipps on Q4 2020 Results - Earnings Call Transcript

Benzinga - 1 month ago

Shares of Omnicell (NASDAQ:OMCL) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 18.18% year over year to $0.91, which bea...

Business Wire - 1 month ago

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell Reports Fiscal Year, Fourth Quarter 2020 Results Record 2020 Total Product Bookings of $1+ billion Full Year 2020 Revenues of $892.2 million

Benzinga - 1 month ago

Omnicell (NASDAQ:OMCL) releases its next round of earnings this Monday, February 01. Get the latest predictions in Benzinga's essential guide to the company's Q4 earnings report.

Zacks Investment Research - 1 month ago

3 Top Medical Info Systems Stocks to Beat COVID-19 Resurgence Crisis

Other stocks mentioned: NH, NXGN
Business Wire - 1 month ago

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--WVU Medicine Selects Omnicell One Intelligence Solution to Drive Better Pharmacy Inventory Management, Optimize Costs, Support Better Patient Care

Zacks Investment Research - 1 month ago

Omnicell (OMCL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 month ago

Per the preliminary announcement, Omnicell (OMCL) projects 2020 total revenues to surpass its previous guidance.

Zacks Investment Research - 1 month ago

Omnicell (OMCL) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Business Wire - 1 month ago

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell Announces Preliminary Fiscal Year 2020 Financial Results

Business Wire - 1 month ago

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell's EnlivenHealth™ Reports Strong Customer Demand for New SaaS Technology Solution to Help Pharmacies Meet COVID-19 Vaccination Challenges

Business Wire - 1 month ago

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell to Partner with Guy's and St Thomas' NHS Foundation Trust, London on Development of European Technology-Enabled Intelligence Centre

Business Wire - 2 months ago

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Owensboro Health to Deploy Omnicell's Technology-Enabled Services to Improve Safety and Efficiency in Medication Management

Forbes - 2 months ago

After a solid 2x rise since March lows of this year, at the current price of around $115 per share, Omnicell stock (NASDAQ: OMCL), a medication management services provider, has reached its ne...

Business Wire - 2 months ago

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell to Present at the J.P. Morgan 39th Annual Healthcare Conference

Zacks Investment Research - 2 months ago

Omnicell (OMCL) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Market Watch - 2 months ago

Baxter International has approached medication management software vendor Omnicell with a takeover bid, Reuters reported, citing people familiar with the matter. Baxter's offer is in excess of...

Business Wire - 3 months ago

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell Announces Latest Advancements in Automation, Intelligence, and Technology-Enabled Services at Omnicell Illuminate 2020

Business Wire - 3 months ago

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Allegheny Health Network Partners with Omnicell to Drive Safety and Efficiency for Medication Management Across Western Pennsylvania Network

Business Wire - 3 months ago

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell to Present at Upcoming Investor Conferences

Seeking Alpha - 4 months ago

Omnicell, Inc. (OMCL) CEO Randall Lipps on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 4 months ago

Omnicell (OMCL) delivered earnings and revenue surprises of 20.00% and 2.39%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 4 months ago

Shares of Omnicell (NASDAQ:OMCL) were flat in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share decreased 21.05% year over year to $0.60, which b...

Business Wire - 4 months ago

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell Reports Third Quarter 2020 Results

Business Wire - 4 months ago

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Lehigh Valley Health Network Chooses Omnicell Solutions to Enhance Clinical and Operational Outcomes and Streamline Medication Management

Zacks Investment Research - 4 months ago

Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 4 months ago

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Memorial Hospital at Gulfport Selects Omnicell Central Pharmacy Dispensing Service to Enhance Medication Safety and Dispensing

Zacks Investment Research - 4 months ago

CPSI vs. OMCL: Which Stock Is the Better Value Option?

Other stocks mentioned: CPSI
Business Wire - 4 months ago

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell Launches EnlivenHealth™ to Aid Retail Pharmacies and Health Plans Improve Patient Adherence, Quality Measures, and Retention

Business Wire - 4 months ago

NEW YORK--(BUSINESS WIRE)--Headline of release should read: Blue Wolf Capital Closes on Sale of Pharmaceutical Strategies Group’s 340B Business to Omnicell (instead of: Blue Wolf Capital Close...

Business Wire - 4 months ago

NEW YORK--(BUSINESS WIRE)--Today, Blue Wolf Capital Partners (“Blue Wolf”), a New York-based private equity firm, announced the completion of the sale of Pharmaceutical Strategies Group’s 340B...

Business Wire - 5 months ago

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell Completes Acquisition of Pharmaceutical Strategy Group’s Leading 340B Software-Enabled Service Business

Business Wire - 5 months ago

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell to Release Third Quarter 2020 Earnings Results on October 27, 2020

The Motley Fool - 5 months ago

The company hasn't yet set the price, interest rate, or other key terms for the securities.

Business Wire - 5 months ago

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell Announces Proposed Private Placement of $500 Million of Convertible Senior Notes

Business Wire - 6 months ago

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell to Present at Upcoming Investor Conferences

Zacks Investment Research - 6 months ago

Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 6 months ago

Omnicell (OMCL) is currently witnessing slowdown in purchasing decisions by hospitals.

Zacks Investment Research - 6 months ago

Omnicell (OMCL) expands pharmacy supply chain capabilities for better management of 340B programs through the buyout of PSG's 340B Link business.

Business Wire - 6 months ago

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Peninsula Regional Medical Center Extends Partnership with Omnicell to Enhance Safety and Efficiency in Sterile Compounding

See It Market - 6 months ago

In today’s article we look at recent news and updates for 3 stocks that my firm has an investment in. Again, I have a personal stake in these companies.

Other stocks mentioned: FB, SQ
Business Wire - 6 months ago

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell to Acquire Pharmaceutical Strategy Group’s Leading 340B Software-Enabled Service Business

Zacks Investment Research - 7 months ago

Omnicell's (OMCL) second-quarter revenues suffered due to slowdown in hospital purchasing decisions and product bookings owing to pandemic-led business disruptions.

Seeking Alpha - 7 months ago

Omnicell, Inc. (OMCL) CEO Randall Lipps on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 7 months ago

Omnicell (OMCL) delivered earnings and revenue surprises of -13.95% and 0.50%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 7 months ago

Shares of Omnicell (NASDAQ:OMCL) rose 1.8% in after-market trading after the company reported Q2 results.

Business Wire - 7 months ago

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell Reports Second Quarter 2020 Results

Business Wire - 7 months ago

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell to Release Second Quarter 2020 Earnings Results on July 28, 2020

Business Wire - 7 months ago

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell Streamlines Pharmacy Supply Chain Through New Cloud-Based Predictive Intelligence Solution, Omnicell One

About OMCL

Omnicell, together with its subsidiaries, provides medication management automation solutions and adherence tools for healthcare systems and pharmacies worldwide. The company offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. It also provides point of care automation solutions ... [Read more...]

Industry
Health Information Services
IPO Date
Aug 7, 2001
CEO
Randall Lipps
Employees
2,860
Stock Exchange
NASDAQ
Ticker Symbol
OMCL
Full Company Profile

Financial Performance

In 2020, Omnicell's revenue was $892.21 million, a decrease of -0.54% compared to the previous year's $897.03 million. Earnings were $32.19 million, a decrease of -47.51%.

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for Omnicell stock is "Buy." The 12-month stock price forecast is 137.00, which is an increase of 5.87% from the latest price.

Price Target
$137.00
(5.87% upside)
Analyst Consensus: Buy